{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-350596","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-08-14T12:30:12+00:00","discovered_at":"2026-08-14T12:35:12.426910+00:00","generated_at":"2026-08-14T12:35:45.572581+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Climb Bio partner Mabworks doses first IgA nephropathy patient in Phase 2 China trial","bullets":["Beijing Mabworks Biotech announced first patient dosed in Phase 2 trial for immunoglobulin A nephropathy in China.","Trial is conducted in collaboration with Climb Bio, Inc.; announcement made August 13, 2026.","Climb Bio disclosed the milestone via Form 8-K on August 14, 2026; no financial terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-350596","json":"https://secwatch.observer/filing/0001193125-26-350596.json","markdown":"https://secwatch.observer/filing/0001193125-26-350596.md","text":"https://secwatch.observer/filing/0001193125-26-350596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526350596/0001193125-26-350596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526350596/d328636d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:35:45.572581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}